TY - JOUR
T1 - Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T
AU - Galli, Eugenio
AU - Di Blasi, Roberta
AU - Pansini, Ilaria
AU - Cristinelli, Caterina
AU - Bommier, Come
AU - De Bernardis, Ilenia
AU - Corrente, Alessandro
AU - Viscovo, Marcello
AU - Montini, Luca
AU - Chiusolo, Patrizia
AU - Hohaus, Stefan
AU - Sora', Federica
AU - Thieblemont, Catherine
AU - Sica, Simona
PY - 2025
Y1 - 2025
N2 - : We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
AB - : We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
KW - CAR‐T
KW - cell therapy
KW - non‐Hodgkin‐S lymphoma
KW - tolerability
KW - CAR‐T
KW - cell therapy
KW - non‐Hodgkin‐S lymphoma
KW - tolerability
UR - https://publicatt.unicatt.it/handle/10807/325421
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=105008751849&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105008751849&origin=inward
U2 - 10.1111/bjh.20222
DO - 10.1111/bjh.20222
M3 - Article
SN - 0007-1048
VL - 207
SP - 642
EP - 647
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -
